文献速递泌尿男性生殖肿瘤

卡巴他赛对比阿比特龙或恩扎卢胺治疗预后不良转移性去势抵抗性前列腺癌:多中心随机开放标签II期试验

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
PubMed 文献 · Ann Oncol · 2021-04-06

一线临床获益率A组优于B组(80% vs 62%,P=0.039),但总生存(中位37.0 vs 15.5个月,HR=0.58,P=0.073)和至进展时间(中位5.3 vs 2.8个月,HR=0.87,P=0.52)无显著差异。基线ctDNA比例高于队列中位数及治疗中ctDNA升高与更短至进展时间相关。

要点

  • 卡巴他赛一线临床获益率高于ARPI(80% vs 62%,P=0.039)。
  • 总生存与至进展时间两组无显著差异。
  • 基线ctDNA>30%者总生存显著短于ctDNA不可测者(HR=38.22,P<0.001)。

核心结论

  • 在ARPI初治预后不良mCRPC中,卡巴他赛较阿比特龙或恩扎卢胺提高一线临床获益率。
  • ctDNA丰度是独立于临床特征的预后标志物,有望用于分层。

研究设计与样本

  • 1:1随机接受卡巴他赛+泼尼松(A组)或医生选择的恩扎卢胺/阿比特龙+泼尼松(B组),标准剂量,进展后可交叉。
  • 主要终点为一线治疗临床获益率(PSA反应≥50%、影像学反应或疾病稳定≥12周)。
  • 中位随访21.9个月。

主要发现

  • 一线临床获益率A组80% vs B组62%(P=0.039)。
  • 总生存中位A组37.0个月 vs B组15.5个月(HR=0.58,P=0.073)。
  • 至进展时间中位A组5.3个月 vs B组2.8个月(HR=0.87,P=0.52)。
  • 基线ctDNA比例高于队列中位数与更短至进展时间相关(HR=2.38,P<0.001)。
  • 治疗中ctDNA升高与更短至进展时间相关(HR=4.03,P<0.001);基线ctDNA>30%者总生存显著短于ctDNA不可测者(HR=38.22,P<0.001)。

关键数值与推荐

  • 预后不良特征包括:肝转移、ADT<12个月进展至mCRPC、或6项临床标准中≥4项。
  • 最常见一线治疗相关≥3级不良事件:中性粒细胞减少(卡巴他赛32% vs ARPI 0%)、腹泻(9% vs 0%)、感染(9% vs 0%)、乏力(7% vs 5%)。

临床怎么用

  • 对ARPI初治预后不良mCRPC,卡巴他赛可提高一线临床获益率,但需权衡血液学毒性。
  • 基线及治疗中ctDNA动态可用于预后分层,高ctDNA提示更差结局。

局限性

  • 开放标签设计,B组为医生选择治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI). We sought to determine optimal treatment in this setting. PATIENTS AND METHODS: This multicentre, randomised, open-label, phase II trial recruited patients with ARPI-naive mCRPC and poor prognosis features (presence of liver metastases, progression to mCRPC after <12 months of androgen deprivation therapy, or ≥4 of 6 clinical criteria). Patients were randomly assigned 1 : 1 to receive cabazitaxel plus prednisone (group A) or physician's choice of enzalutamide or abiraterone plus prednisone (group B) at standard doses. Patients could cross over at progression. The primary endpoint was clinical benefit rate for first-line treatment (defined as prostate-specific antigen response ≥50%, radiographic response, or stable disease ≥12 weeks). RESULTS: Ninety-five patients were accrued (median follow-up 21.9 months). First-line clinical benefit rate was greater in group A versus group B (80% versus 62%, P = 0.039). Overall survival was not different between groups A and B (median 37.0 versus 15.5 months, hazard ratio (HR) = 0.58, P = 0.073) nor was time to progression (median 5.3 versus 2.8 months, HR = 0.87, P = 0.52). The most common first-line treatment-related grade ≥3 adverse events were neutropenia (cabazitaxel 32% versus ARPI 0%), diarrhoea (9% versus 0%), infection (9% versus 0%), and fatigue (7% versus 5%). Baseline circulating tumour DNA (ctDNA) fraction above the cohort median and on-treatment ctDNA increase were associated with shorter time to progression (HR = 2.38, P < 0.001; HR = 4.03, P < 0.001). Patients with >30% ctDNA fraction at baseline had markedly shorter overall survival than those with undetectable ctDNA (HR = 38.22, P < 0.001). CONCLUSIONS: Cabazitaxel was associated with a higher clinical benefit rate in patients with ARPI-naive poor prognosis mCRPC. ctDNA abundance was prognostic independent of clinical features, and holds promise as a stratification biomarker.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Annala M, Fu S, Bacon JVW, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021. PMID: 33836265. doi:10.1016/j.annonc.2021.03.205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。